...
机译:P1.01-20期III研究将Gefitinib(g)与Gefitinib与Carboplatin和Pemetrexed(GCP)与EGFR突变(NEJ009)相结合的研究
Department of Respiratory Medicine Miyagi Cancer Center;
Department of Palliative Medicine Tohoku University School of Medicine;
Department of Biomedical Statistics and Bioinformatics Kyoto University Graduate School of Medicine;
Department of Pulmonary Medicine Sendai Kousei Hospital;
Department of Thoracic Oncology and Respiratory Medicine Tokyo Metropolitan Cancer and Infectious;
Division of Respiratory Medicine Kanagawa Cardiovascular and Respiratory Center;
Department of Pulmonary Medicine and Oncology Nippon Medical School;
Juntendo University Faculty of Medicine and Graduate School of Medicine;
Asahikawa Medical Center;
Jcho Hokkaido Hospital;
Gunma Prefectural Cancer Center;
First Department of Mediine Obihiro Kosei General Hospital;
Saitama Medical University;
Tohoku University;
机译:P1.01-20期III研究将Gefitinib(g)与Gefitinib与Carboplatin和Pemetrexed(GCP)与EGFR突变(NEJ009)相结合的研究
机译:9LBA一项将吉非替尼与卡铂(CBDCA)加紫杉醇(TXL)用于具有敏感EGFR突变的非小细胞肺癌(NSCLC)一线治疗的随机III期研究:NEJ002研究
机译:P2.06-023 A III期研究将Gefitinib和插入的顺铂加上吉替尼与Gefitinib进行EGFR-突变的高级非鳞状NSCLC的研究
机译:在气相中研究的DNA构建块与DNA构建块的相互作用:一种实验与理论研究
机译:吉非替尼或培美曲塞联合卡铂治疗EGFR突变的晚期肺腺癌的III期研究
机译:P1.01-20期III研究将Gefitinib(g)与Gefitinib与Carboplatin和Pemetrexed(GCP)与EGFR突变(NEJ009)相结合的研究